Navigation Links
Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease
Date:10/31/2009

Alexandria, VA Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology Head and Neck Surgery.

According to the authors, gastroesophageal reflux(GERD) and laryngopharyngeal reflux (LPR) are diseases that have undergone a remarkable growth in public health relevance over the last 20 years. While it has been known historically that more than 50 percent of adults in Western countries have occasional symptoms of reflux, there has been a more than four-fold increase in how many patients seek medical care for their symptoms.

PPIs are a class of important and generally safe medicines that prevent the release of stomach acid, which is one cause of the burning sensation many reflux patients experience. PPIs are among the most widely prescribed classes of medications for GERD and LPR diseases. But according to the authors, there is a growing body of literature demonstrating that acid is not the only causal agent of tissue damage in reflux disease, and that PPIs are not effective at treating all cases of GERD and LPR.

In addition to the evidence that acid isn't the only contributing agent in reflux disease, the authors' search of recent research on PPIs pointed out that there are many unexpected consequences and side effects from this class of drugs. They can include: increased rates of hip fractures, possibly related to altered calcium absorption; possible but yet unproven altered vitamin B12 and iron absorption, related to alteration of the gastric pH; increased odds of acquiring nosocomial Clostridium difficile-associated diarrhea; and increased odds of contracting community-acquired pneumonia.

The authors say while it may be premature to make global recommendations about PPI prescribing patterns, they applaud the idea of raising clinical awareness of this medication class and its potential unexpected consequences. In addition, appropriate evaluation and monitoring of patients taking PPIs will be important in determining the need and duration of the use of the medications. The authors further advise physicians treating reflux disease patients to weigh the risks of treatment versus the risks of not treating the disease, and to consider a goal of a more holistic approach that includes diet and lifestyle modification. These additional steps could prove beneficial in lowering healthcare costs associated with reflux diseases, and encourage patients to continue practicing behaviors that would improve their overall health.


'/>"/>

Contact: Jessica Mikulski
newsroom@entnet.org
703-535-3762
American Academy of Otolaryngology -- Head and Neck Surgery
Source:Eurekalert

Related medicine news :

1. Cinergy Health Commentary on Americas Prescription Addiction
2. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
3. Taming Wide Variations in Spending Key to Health Reform - New England Journal of Medicine Commentary from Dartmouth Atlas Project
4. AANMA Provides Commentary to FDA Advisory Committees Reviewing Benefit-Risk Assessment of 12 Hour Bronchodilators
5. Commentary in The Lancet on the Declaration of Istanbul Sees Organ Transplantation Worldwide Threatened by Organ Trafficking and Transplant Tourism and Commercialism
6. FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet
7. Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset
8. Letter Warns About Tricky Dosing With Liquid Tamiflu for Kids
9. VA Warns Veterans of Telephone Prescription Scam
10. FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution
11. Social Security Advisory Board Warns of Consequences of Unsustainable Growth in The Cost of Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Last year, 43 million ... US Department of Agriculture report. While excess dairy can be caused by several ... Lactose sensitivity is the inability to properly digest lactose, a sugar found in milk ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo ... Jersey and the New York metropolitan region, is embarking on a cooperative charity ... families. , At present, more than two and a half million children in ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a ... greater Nassau County region, is embarking on a combined charity effort with the Great ... For the last 25 years, the Great Neck Breast Cancer Coalition has worked to ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Jim Shortridge Agency, ... and business owners, is joining the Teen Recovery Solutions organization in a charity ... A growing number of Oklahoma teens and adolescents face problems from drugs, alcohol, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to families and business owners in the greater Nassau County area, ... & Lymphoma Society. , Every 3 minutes, someone in America is diagnosed with ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 A new ... Disinfector™ is the proven ultraviolet-C (UV-C) disinfection solution ... infections (HAIs). Published in the ... Infection Control , the peer-reviewed study of UV-C ... of Vancouver General Hospital and Rochester General Hospital. ...
(Date:3/22/2017)... -- FinancialBuzz.com News Commentary  ... According to a report by the New Frontier ... in 2016, and is projected to grow at a compound annual ... by 2025. The medical cannabis market is projected to grow at ... to an estimated $13.3 billion in 2025. These projections do not ...
(Date:3/22/2017)... -- TFS is pleased to announce the appointment of ... two global executive positions in Medical Affairs and Clinical Development. Dr. ... and will report to Dr. Montse BarcelĂł , Chief Operating ... ... of medical and scientific expertise gained across leading biopharmaceutical companies and ...
Breaking Medicine Technology: